Decker Eric P, Vasauskas Audrey A
Anesthesiology, Alabama College of Osteopathic Medicine, Dothan, USA.
Molecular Medicine, Alabama College of Osteopathic Medicine, Dothan, USA.
Cureus. 2020 Sep 2;12(9):e10196. doi: 10.7759/cureus.10196.
Acute respiratory distress syndrome (ARDS) is a potentially fatal lung injury that can present with divergent underlying cause across cases. Current treatment options are limited by an incomplete understanding of the disease sequelae, undefined unifying pathology, and lack of reliable diagnostic tools. ARDS is defined as respiratory failure not caused by fluid overload or cardiac failure within one week of a known clinical insult with bilateral opacities on chest imaging, and diagnosis is based on these parameters. Increased understanding of the inflammatory cascade associated with ARDS progression shows promise for identifying potential diagnostic biomarkers and additional treatment options. Here, we review recent studies that point to the unifying inflammatory element(s) of the disease process and the use of agents that decrease inflammation as potentially powerful treatments for ARDS patients.
急性呼吸窘迫综合征(ARDS)是一种潜在致命的肺损伤,不同病例的潜在病因可能各不相同。目前的治疗选择受到对疾病后遗症认识不足、未明确的统一病理学以及缺乏可靠诊断工具的限制。ARDS被定义为在已知临床损伤后一周内,由非液体超负荷或心力衰竭导致的呼吸衰竭,胸部影像学显示双侧混浊,诊断基于这些参数。对与ARDS进展相关的炎症级联反应的深入了解,为识别潜在的诊断生物标志物和其他治疗选择带来了希望。在此,我们回顾了近期的研究,这些研究指出了疾病过程中统一的炎症因素,以及使用减轻炎症的药物作为ARDS患者潜在的有效治疗方法。